Industry Support of CME - the Solution, not the Problem?
This article was originally published in RAJ Devices
As doctors in the US brace themselves for the 30 million new patients that the new healthcare reform law promises to channel into the system, a key mechanism for advancing their medical knowledge and performance is facing tumultuous times.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.